Arquivos do dia: Junho 22, 2021
[Preprint] Rápida substituição da variante B.1.1.7 (Alfa) do SARS-CoV-2 pelas variantes B.1.617.2 (Delta) e P.1 (Gama) nos Estados Unidos.
22 Jun, 2021 | 09:14hRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Comentário no Twitter
🆕💥💥Preprint
📌B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
📌B.1.617.2 will soon be the dominant variant in the US
📌B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward 🇵🇸💔Bassam Ghanem (@ABsteward) June 22, 2021
Perspectiva | COVID-19: ascensão e ascensão de Delta.
22 Jun, 2021 | 09:13hCOVID-19: The rise and rise of Delta – Sciblogs
Ivermectina é a nova hidroxicloroquina, parte 2 – “Ivermectina não deve ser usada no tratamento da COVID-19 fora do contexto de um estudo clínico.”
22 Jun, 2021 | 09:11hIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Relacionado: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance E M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection E Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials E EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials E FDA: Why you should not use Ivermectin to treat or prevent COVID-19 E RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 E NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” E Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Diretrizes para relatar protocolos de estudos e ensaios concluídos modificados pela pandemia de COVID-19 e outras circunstâncias extenuantes: Diretriz CONSERVE 2021.
22 Jun, 2021 | 09:10h
Comentários no Twitter
CONSERVE offers guidance that could help improve the transparency, quality, and completeness of reporting important modifications to trials in extenuating circumstances https://t.co/IiWgs7dtpQ
— JAMA (@JAMA_current) June 21, 2021
Did your clinical trial require modification due to #COVID19? Check out these reporting guidelines in @JAMA_current. https://t.co/Oy21gmrRlN
— Sherry Pagoto (@DrSherryPagoto) June 21, 2021
Relato de caso | Síndrome inflamatória multissistêmica em adulto após infecção por SARS-CoV-2.
22 Jun, 2021 | 09:09hSinopse de diretriz | Tratamento da pressão arterial em pacientes com doença renal crônica não dialítica.
22 Jun, 2021 | 09:08hDiretriz original: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Comentário: Guideline issued on blood pressure management in CKD – ACP Internist
AGS publica as Competências Geriátricas Mínimas para Estudantes de Medicina.
22 Jun, 2021 | 09:07hComunicado de imprensa: AGS publishes updated AGS Minimum Geriatrics Competencies for Graduating Medical Students – American Geriatrics Society
Recomendações: Minimum Geriatric Competencies for Medical Students
Recomendações do consenso 2021 MAGNIMS–CMSC–NAIMS para o uso de ressonância magnética em pacientes com esclerose múltipla.
22 Jun, 2021 | 09:06h2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis – The Lancet Neurology (necessário cadastro gratuito)
Comentário no Twitter
ONLINE FIRST: The 2021 MAGNIMS–CMSC–NAIMS international consensus recommendations on MRI in patients with multiple sclerosis provide updated guidance on how and when to use MRI for diagnosis, prognosis, and treatment monitoring of multiple sclerosishttps://t.co/bLnRo40tgw
— The Lancet Neurology (@TheLancetNeuro) June 15, 2021
Estudo mostra excesso de uso de levotiroxina em pacientes com hipotireoidismo subclínico, apesar das evidências mostrarem que não há benefício.
22 Jun, 2021 | 09:05hLevothyroxine Use in the United States, 2008-2018 (gratuito por tempo limitado)
Editorial: Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to “Leve”-Out-Thyroxine – JAMA Internal Medicine (gratuito por tempo limitado)
Relacionado: RCT: Levothyroxine does not reduce the risk of developing depressive symptoms in older adults with subclinical hypothyroidism (estudos e diretrizes sobre o tema)
Análise do especialista | O papel cada vez maior do escore de cálcio das artérias coronárias na prevenção primária.
22 Jun, 2021 | 09:04h
Comentário no Twitter
New ACC Expert Analysis: The Ever-Growing Role of Coronary Artery Calcium in Primary Prevention.
More: https://t.co/GSsEqkoMbi @miguelcainzos23 @rblument1 @AndyGagel #ASCVD #cvPrev pic.twitter.com/7cUOAIArz9
— American College of Cardiology (@ACCinTouch) June 22, 2021